D016903ProceduresE01.370.520.20010190.983245Drug Monitoringcmhprofilesont:personsuffixperson suffixFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentDivisionvivo:hrJobTitleHR job titleInformation Resourcevivo:orcidIdORCID idPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson2.185870.026978310research area of0.8179370.10019622subject area forMD, MPHAlanGamisAlan S. Gamis0.000000000000000.0000000000000049Gamis, Alan0000-0003-1513-2893Chief, Section of OncologyMDJenniferGoldmanJennifer L. Goldman87Goldman, JenniferDirector, Drug Safety Service2Associate Professor1Professor27111148Goldman JL, Abdel-Rahman SMExpert opinion on drug metabolism & toxicologyGoldman JL, Abdel-Rahman SM. Pharmacokinetic considerations in treating invasive pediatric fungal infections. Expert Opin Drug Metab Toxicol. 2016 Jun; 12(6):645-55.Expert Opin Drug Metab Toxicol2016-05-05T00:00:002016Pharmacokinetic considerations in treating invasive pediatric fungal infections.Pathology and Laboratory MedicinePediatricsResearchClinicalPhDKathyGogginKathy Goggin0.000000000000000.0000000000000015Goggin, KathyErnest L. Glasscock, MD, Chair in Education and ResearchChildren's Mercy Kansas CityMD, PhD, FCAPMidhatFarooqiMidhat Farooqi0.000000000000000.00000000000000161Farooqi, Midhat0000-0002-5238-1349Director, Molecular Oncology, Center for Pediatric Genomic Medicine32716487Burns AN, Goldman JLJournal of the Pediatric Infectious Diseases SocietyBurns AN, Goldman JL. A Moving Target-Vancomycin Therapeutic Monitoring. J Pediatric Infect Dis Soc. 2020 Sep 17; 9(4):474-478.J Pediatric Infect Dis Soc2020-09-17T00:00:002020A Moving Target-Vancomycin Therapeutic Monitoring.MD, FAAP, FACMG, CCDEricRushEric T. Rush0.000000000000000.00000000000000200Rush, Eric0000-0002-8147-7315Medical Director, Office of Faculty Affairs and Development28888853Kishnani PS, Rush ET, Arundel P, Bishop N, Dahir K, Fraser W, Harmatz P, Linglart A, Munns CF, Nunes ME, Saal HM, Seefried L, Ozono KMolecular genetics and metabolismKishnani PS, Rush ET, Arundel P, Bishop N, Dahir K, Fraser W, Harmatz P, Linglart A, Munns CF, Nunes ME, Saal HM, Seefried L, Ozono K. Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa. Mol Genet Metab. 2017 09; 122(1-2):4-17.Mol Genet Metab2017-07-25T00:00:002017Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa.33539569Downes KJ, Goldman JLClinical pharmacology and therapeuticsDownes KJ, Goldman JL. Too Much of a Good Thing: Defining Antimicrobial Therapeutic Targets to Minimize Toxicity. Clin Pharmacol Ther. 2021 04; 109(4):905-917.Clin Pharmacol Ther2021-02-27T00:00:002021Too Much of a Good Thing: Defining Antimicrobial Therapeutic Targets to Minimize Toxicity.33933127Funk RS, Shakhnovich V, Cho YK, Polireddy K, Jausurawong T, Gress K, Becker MLPediatric rheumatology online journalFunk RS, Shakhnovich V, Cho YK, Polireddy K, Jausurawong T, Gress K, Becker ML. Factors associated with reduced infliximab exposure in the treatment of pediatric autoimmune disorders: a cross-sectional prospective convenience sampling study. Pediatr Rheumatol Online J. 2021 May 01; 19(1):62.Pediatr Rheumatol Online J2021-05-01T00:00:002021Factors associated with reduced infliximab exposure in the treatment of pediatric autoimmune disorders: a cross-sectional prospective convenience sampling study.true1Ernest L. Glasscock, MD, Chair in Education and ResearchErnest L. Glasscock, MD, Chair in Education and Researchtrue1Director, Molecular Oncology, Center for Pediatric Genomic MedicineDirector, Molecular Oncology, Center for Pediatric Genomic Medicinetrue1Chief, Section of OncologyChief, Section of Oncologytrue1Director, Drug Safety ServiceDirector, Drug Safety Servicetrue1Medical Director, Office of Faculty Affairs and DevelopmentMedical Director, Office of Faculty Affairs and Development